Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Keyphrases

• Continuous Infusion 100%
• Oxaliplatin 100%
• Unresectable Liver Metastases 100%
• Colorectal Cancer Liver Metastasis (CRCLM) 100%
• Bolus 20%
• Liver 20%
• Metastasis 20%
• Stable Disease 20%
• Partial Response 20%
• Nausea 20%
• Chemotherapy 20%
• Colorectal Cancer 20%
• Toxicity Profile 20%
• Hepatitis 20%
• High Response Rate 20%
• Dose-limiting Toxicity 20%
• Response Rate 20%
• Surgical Removal 20%
• Asthenia 20%
• Curative Intent 20%
• 1-year Mortality 20%
• Abdominal Pain 20%
• Platinum Compounds 20%
• Toxicity Grades 20%
• Chronic Abdominal Pain 20%
• Primary Sclerosing Cholangitis 20%
• Endoscopic Retrograde Cholangiopancreatography 20%
• Fluoropyrimidine 20%
• No-chemical 20%
• 5-FU Resistance 20%
• Tumor Growth Control 20%

Medicine and Dentistry

• Continuous Infusion 100%
• Oxaliplatin 100%
• Liver Metastasis 100%
• Colorectal Carcinoma 100%
• Abdominal Pain 40%
• Diseases 40%
• Infusion 20%
• Metastatic Carcinoma 20%
• Nausea 20%
• Tumor Progression 20%
• Survival Rate 20%
• Endoscopic Retrograde Cholangiopancreatography 20%
• Platinum Derivative 20%
• Growth Regulation 20%
• Hepatitis 20%
• Fluoropyrimidine 20%
• Sclerosing Cholangitis 20%
• Asthenia 20%
• Chemotherapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Oxaliplatin 100%
• Liver Metastasis 100%
• Colorectal Carcinoma 100%
• Abdominal Pain 40%
• Diseases 40%
• Nausea 20%
• Tumor Growth 20%
• Asthenia 20%
• Survival Rate 20%
• Chemotherapy Regimens 20%
• Platinum Derivative 20%
• Hepatitis 20%
• Fluoropyrimidine 20%
• Sclerosing Cholangitis 20%